GlassScriptPhysician profile
Thomas J Farchone
NPI 1063476844
$1,011.80
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $353.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $168.92 | 2019-2020 | |
| Novo Nordisk INC | $156.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $82.93 | 2019-2020 | |
| Astellas Pharma US INC | $78.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $75.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $74.40 | 2019-2020 | |
| Allergan, INC. | $55.57 | 2019-2020 | |
| Lilly USA, LLC | $40.48 | 2019-2020 | |
| Abbvie INC. | $38.61 | 2019-2020 | |
| Janssen Biotech, INC. | $38.37 | 2019 | |
| Glaxosmithkline, LLC. | $22.59 | 2019 | |
| Bioventus LLC | $17.27 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.82 | 2019 | |
| Amarin Pharma, INC. | $15.42 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $15.23 | 2020 | |
| Pfizer INC. | $14.20 | 2019 | |
| Celgene Corporation | $13.81 | 2019 | |
| Merck Sharp & Dohme LLC | $10.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Farchone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.